Search Results

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

involves alveolar differentiation of mammary epithelial cells (MECs), which is essential for breast milk assessing changes in cellular viability, lipid accumulation, and gene and protein expression of major milk We hypothesized that THC and CBD will negatively impact the synthesis of milk proteins and lipids, as Relative to control, 10μM THC and 10μM CBD reduced mRNA levels of milk proteins (CSN2 and WAP), lipid

September 2022 Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model of mild

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million , including an investment of $3 million from Virtus Inspire Venture Partners.

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million

The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Capital LLC, a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“ADSs”) at a gross purchase price of $6.50 per ADS, which is equivalent to CHF 1.00 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered warrants to purchase up to 9,230,772 shares in the form of 1,538,462 ADSs (the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares in the form of 913,095 ADSs (the “Unregistered Pre-Funded Warrants” and together with the Unregistered Warrants, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $6.50 per ADS, will become exercisable in 60 days after their date of issuance and will expire six years from their date of issuance. The Unregistered Pre-Funded Warrants have been funded to the amount of $6.49 with $0.01 payable on exercise." Read more at the source #DrGPCR #GPCR #IndustryNews

July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a healthcare-focused institutional investor, to sell 3,300,000 shares in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded Warrants”, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR #IndustryNews

Miles Thompson, Alexander Hauser, Caroline Gorvin et al. for their research on GPCR gene variants and Get started by filling out this form!

Hauser on receiving 4.8 mill DKK from Carlsberg Foundation’s Semper Ardens: Accelerate programme.

GPCR Team This Week’s Highlights: Congratulations to Andrew Tobin for an incredible week filled with fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan

Brian Krumm and Bryan Roth studied CryoEM structures of adhesion in GPCR CD97, filling gaps. For those who joined any of our symposium sessions, we kindly request a moment of your time to fill out Adhesion GPCRs CryoEM structures of adhesion in GPCR CD97: Filling in some of the gaps GPCR Activation

Classified GPCR News from October 21st to 27th, 2024 Industry News UNC School of Medicine to Receive $3-Million fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Chemistry GPCR Activation and Signaling A gain of function variant in RGS18 candidate for a familial mild

Graeme Milligan for receiving the Order of British Empire from King Charles III in recognition of his If you're interested in presenting a poster, simply fill out the submission form and submit a 1-minute Graeme Milligan was awarded the Order of British Empire by King Charles III for services to Biochemical

Take 2 minutes to fill out this survey and let us know what you liked, what you didn’t, and what we can GPCR University have been filled! Thank you for the overwhelming response. Please fill out the waitlist form. We'll let you know if any spots become available. Dr.

This week's highlight includes congrats to: Miles Thompson , Alexander Hauser , Caroline Gorvin ,   et Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million

3 out of the 25 spots have been filled! Team Registrations are also available! To begin, please fill out this form!

Our findings fill a gap in the understanding of CB1 allosteric regulation and could guide the rational

cell type–specific roles for C3aR in regulating innate immune cell inflammatory state, antimicrobial killing

In this context, mutagenesis has emerged as an "old-school" but essential technology to fill these knowledge cryo-electron microscopy have deepened our understanding of ligand-receptor interactions, mutagenesis fills

For example, chemotherapy, a powerful standard approach to kill fast-growing cancer cells, has the drawback

session in breakout rooms on Zoom; if you are interested in sharing your work with our community, kindly fill Additionally, if you participated in our Symposia in 2023, please take a moment to fill out this survey

Taken together, our study fills the missing information of GPCR/G-protein engagement and provides a framework

study on Cell swelling enhances ligand-driven β-adrenergic signaling ✨ Reserve Your seat before these fill Classified GPCR News from September 2nd to 8th, 2024 Industry News Superluminal Medicines Closes $120 Million Congress of Basic and Clinical Pharmacology GPCR Jobs HIGHLIGHT Research Associate - Professor Graeme Milligan

17 out of the 25 spots have been filled! Team Registrations are also available!  Fill out this form to get started!

This Week’s Highlights: G protein-coupled receptor (GPCR) pharmacogenomics Miles D Thompson , David fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan

session in breakout rooms on Zoom; if you are interested in sharing your work with our community, kindly fill Additionally, if you participated in our Symposia in 2023, please take a moment to fill out this survey